# Metastatic Uveal Melanoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-uveal-melanoma

> 4 upcoming FDA catalysts in metastatic Uveal Melanoma: darovasertib (IDYA) on Jan to Apr 2027 (topline data readout); darovasertib (IDYA) on January 2027 (primary completion); rp2 (REPL) on January 2030 (primary completion); rp2 (REPL) on Jan to Apr 2030 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan to Apr 2027 | [Darovasertib topline data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA | Metastatic Uveal Melanoma | scheduled | "NCT05987332 (IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05987332)) |
| January 2027 | [Darovasertib primary completion](https://sec-api.dev/pdufa/darovasertib) | IDYA | Metastatic Uveal Melanoma | scheduled | "NCT05987332 (IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05987332)) |
| January 2030 | [Rp2 primary completion](https://sec-api.dev/pdufa/rp2) | REPL | Metastatic Uveal Melanoma | scheduled | "NCT06581406 (A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Replimune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06581406)) |
| Jan to Apr 2030 | [Rp2 topline data readout](https://sec-api.dev/pdufa/rp2) | REPL | Metastatic Uveal Melanoma | scheduled | "NCT06581406 (A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Replimune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06581406)) |

## Drugs

- [Darovasertib](https://sec-api.dev/pdufa/darovasertib) (IDYA)
- [Rp2](https://sec-api.dev/pdufa/rp2) (REPL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-uveal-melanoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Metastatic Uveal Melanoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-uveal-melanoma

```bibtex
@misc{secapidev_indications_metastatic_uveal_melanoma_20261116,
  title        = {Metastatic Uveal Melanoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-uveal-melanoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_uveal_melanoma_20261116","title":"Metastatic Uveal Melanoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-uveal-melanoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
